Robotic surgical system maker Intuitive Surgical (NASDAQ: ISRG ) has taken its share of blows lately. From questions over the company's training of surgeons qualified to use its da Vinci surgical system, to lawsuits cropping up regarding patient injuries during operations, all eyes are on how this leading medical device innovator will handle the pressure.
Now, the FDA has jumped in, citing Intuitive Surgical with a failure to first notify agency regulators about a caution letter regarding the da Vinci it sent to customers in 2011. The notice hit Intuitive's stock on after-hours trading on Tuesday and early Wednesday morning; but should you be concerned about the latest questions over this company's business? Motley Fool contributor Dan Carroll tells you what you need to know about Intuitive Surgical's future below.
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.